Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...

Viatris will likely encounter additional write-downs and impairments, along with macroeconomic headwinds. Click here to find ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Novo Nordisk NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

After two years of stellar market returns, U.S. investors have dialed back their expected average annual investment returns to a level that’s 21% below 2023’s level. 73% of U.S. investors are ...

The reason Novo Nordisk is losing patent protection is because it wouldn't pay a couple hundred bucks. In 2019, the Canadian patent office sent a letter saying it hadn't received Novo Nordisk's annual ...